Isakovic 2019 MiP2019

From Bioblast
Jump to: navigation, search
Andjelka Isakovic
The role of ROS in antileukemic action of ethyl ester compound and corresponding Pt(II) and Pt(IV) complexes.

Link: MiP2019

Isakovic AM, Poljarevic J, Sabo TJ, Grguric-Sipka S, Markovic I, Misirlic-Dencic S (2019)

Event: MiP2019

COST Action MitoEAGLE

Blood cancers account for more than 10% of new malignancies and are expected to account for 9.4% of the deaths from cancer in 2019. As chemotherapy is used to treat most types of blood cancers, the search for new and more effective drugs is ongoing.

The aim of this study was to investigate the role of ROS in antileukemic action of Pt(II) and Pt(IV) complexes with ethyl ester compound.

Cytotoxic action of ethyl ester ligand and corresponding Pt complexes was investigated in human promyelocytic (HL-60) cell line. Cell viability was assessed by acid phosphatase and LDH assay, while ROS production and cell death parameters were analyzed by flow cytometry.

The results showed Pt(II) complex was more potent in antileukemic action than corresponding Pt(IV) complex, through induction of ROS production and apoptosis, evidenced by caspase activation and phosphatidylserine externalization. Organic ethyl ester ligand was quite efficient itself, even more than corresponding Pt(IV) complex regarding IC50 value.

Obtained results suggest that Pt(II) complexes with this type of organic ligand could have better antileukemic potential than corresponding Pt(IV) complexes and warrant further research.

Keywords: Platinum complexes, Antileukemic, ROS, Apoptosis Bioblast editor: Plangger M, Tindle-Solomon L


Labels: MiParea: Pharmacology;toxicology  Pathology: Cancer  Stress:Oxidative stress;RONS  Organism: Human  Tissue;cell: Blood cells 





Affiliations

Isakovic AM(1), Poljarević J(2), Sabo TJ(2), Grgurić-Šipka S(2), Markovic I(1), Misirlic-Dencic S(1)
  1. Inst Medical Clinical Biochemistry, Fac Medicine
  2. Fac Chemistry; Univ Belgrade, Belgrade, Serbia